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Objectives: Studies of neurocognitively elite older adults, termed SuperAgers, have identified clinical predictors and
neurobiological indicators of resilience against age-related neurocognitive decline. Despite rising rates of older persons
living with HIV (PLWH), SuperAging (SA) in PLWH remains undefined. We aimed to establish neuropsychological cri-
teria for SA in PLWH and examined clinically relevant correlates of SA. Methods: 734 PLWH and 123 HIV-uninfected
participants between 50 and 64 years of age underwent neuropsychological and neuromedical evaluations. SA was
defined as demographically corrected (i.e., sex, race/ethnicity, education) global neurocognitive performance within nor-
mal range for 25-year-olds. Remaining participants were labeled cognitively normal (CN) or impaired (CI) based on
actual age. Chi-square and analysis of variance tests examined HIV group differences on neurocognitive status and demo-
graphics. Within PLWH, neurocognitive status differences were tested on HIV disease characteristics, medical comorbid-
ities, and everyday functioning. Multinomial logistic regression explored independent predictors of neurocognitive status.
Results: Neurocognitive status rates and demographic characteristics differed between PLWH (SA= 17%; CN= 38%;
CI= 45%) and HIV-uninfected participants (SA= 35%; CN= 55%; CI= 11%). In PLWH, neurocognitive groups were
comparable on demographic and HIV disease characteristics. Younger age, higher verbal IQ, absence of diabetes, fewer
depressive symptoms, and lifetime cannabis use disorder increased likelihood of SA. SA reported increased independence
in everyday functioning, employment, and health-related quality of life than non-SA. Conclusions: Despite combined
neurological risk of aging and HIV, youthful neurocognitive performance is possible for older PLWH. SA relates to
improved real-world functioning and may be better explained by cognitive reserve and maintenance of cardiometabolic
and mental health than HIV disease severity. Future research investigating biomarker and lifestyle (e.g., physical activity)
correlates of SA may help identify modifiable neuroprotective factors against HIV-related neurobiological aging. (JINS,
2019, 25, 507–519)
Keywords: Neuropsychology, Cognitive reserve, Cognitive decline, Diabetes, Cannabis, Acquired Immunodeficiency
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INTRODUCTION
Antiretroviral therapy (ART) has facilitated increased life
expectancy for people living with HIV (PLWH;Wing, 2016).
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In 2014, 45% of PLWH in the United States were over the
age of 50 (Centers for Disease Control and Prevention, 2018)
and this proportion is expected to increase (Smit et al., 2015).
HIV-associated neurocognitive disorder (HAND) affects
approximately half of PLWH (Heaton et al., 2010; Norman
et al., 2011; Saloner & Cysique, 2017), and older PLWH are
at three times higher risk for HAND compared to younger
PLWH (Valcour et al., 2004). Furthermore, there is evidence
to suggest that HIV accelerates and accentuates neurocogni-
tive aging (Pathai, Bajillan, Landay, & High, 2014; Sheppard
et al., 2017). Older PLWH are at increased risk for functional
decline (Thames et al., 2011; Vance, Fazeli, & Gakumo,
2013), which is not only costly, but also negatively affects
quality of life (Morgan et al., 2012). Identifying factors that
promote successful cognitive aging with HIV and developing
interventions to sustain or enhance themmay avoid or reverse
the adverse effects of aging.
While definitions of successful cognitive aging in PLWH
differ slightly, all definitions require individuals to be neu-
rocognitively unimpaired and functionally independent
(Malaspina et al., 2011; Moore et al., 2017). Successful
cognitive aging rates in older PLWH range from 19–32%,
and translates into real-world benefits, including greater
success in managing medication and medical appointments,
less decline in activities of daily living, and better psycholo-
gical health and health-related quality of life (HRQoL)
(Malaspina et al., 2011;Moore et al., 2017, 2014). Given that the
neuropsychological criteria for successful cognitive aging solely
requires the absence of neurocognitive impairment, taking into
consideration age, there likely remains considerable hetero-
geneity in neurocognitive performance (e.g., low average to
superior) among the successful cognitive aging group.
Thus, distinguishing older PLWH with superior neurocognitive
abilities from those with average neurocognitive abilities may
explain additional variance in everyday functioning outcomes.
Older adults with preserved cognition appear to resist
“normal” age-related decline. The term SuperAger refers to
older adults that perform equivalently to young or middle-
aged adults on episodic memory tests (Harrison, Maass,
Baker, & Jagust, 2018; Rogalski et al., 2013; Sun et al.,
2016). Alternatively, others have researched “Super-
Normals” or “Optimal Memory Performers” – older adults
who demonstrate above-average episodic memory perfor-
mance in comparison to average older adults (Dekhtyar et al.,
2017; Lin et al., 2017; Mapstone et al., 2017; Wang et al.,
2019). Both definitions provide evidence that older adults
with superior memory perform better on other cognitive
domains, particularly executive functioning (Dekhtyar et al.,
2017; Gefen et al., 2015) and processing speed (Dekhtyar
et al., 2017; Harrison et al., 2018).
Additionally, SuperAgers have larger volumes of the cerebral
cortex, hippocampus, and cingulate cortex (Dekhtyar et al.,
2017; Harrison et al., 2018; Lin et al., 2017; Rogalski et al.,
2013; Sun et al., 2016;Wang et al., 2019) as well as slower rates
of cortical atrophy (Cook et al., 2017). Furthermore, Super-
Agers display lower levels of biomarkers of neurodegeneration
such as oxidative stress (Mapstone et al., 2017), inflammation
(Bott et al., 2017), and amyloid (Lin et al., 2017; Rogalski et al.,
2013) and tau deposition (Gefen et al., 2015).
Despite not having a gold-standard definition of Super-
Aging (SA) or preserved cognition, commonalities exist
among the definitions. Most studies have classified Super-
Agers based on superior memory performance alone and only
required either average age-adjusted performance for a few
other neuropsychological measures (Harrison et al., 2018;
Rogalski et al., 2013). Some have required that they be
otherwise neurocognitively normal (Dekhtyar et al., 2017;
Lin et al., 2017). Thus, SA studies predominantly focus on
superior memory performance rather than superior global
neurocognitive performance.
The majority of these studies, which consist of primarily
septua- and octogenarians, require SuperAgers to perform
equivalent to or better than those in their mid-50s; however,
most neurocognitive abilities peak in the mid-20s and then
begin to decline (Hartshorne & Germine, 2015; Heaton,
Taylor, & Manly, 2003; Salthouse, 2003, 2009). Although
SA is typically evaluated in healthy adults who are at least
60 years old, the aging population of PLWH is younger with
50 years old serving as a cutoff for defining a medically
advanced age (Blanco et al., 2012). Nevertheless, neuro-
cognitive aging studies have demonstrated substantial inter-
individual variability in neurocognition for healthy adult cohorts
below the age of 60 (Lachman, Teshale, & Agrigoroaei, 2015;
Martin & Zimprich, 2005; Schaie &Willis, 2010). Importantly,
this heterogeneity in neurocognition tracks with variation in
biopsychosocial factors such that high neurocognitive perfor-
mance correlates with high cognitive reserve and low comor-
bidity burden (Anstey, Sargent-Cox, Garde, Cherbuin, &
Butterworth, 2014; Ferreira et al., 2017).
While current definitions of SA may be appropriate for
studying healthy older adults resistant to the clinical expres-
sions of biological aging and Alzheimer’s disease, SA criteria
should be tailored for study in older PLWH who are younger
and at greater risk for multi-domain neurocognitive decline
rather than focal memory deficits. Thus, we aimed to:
(1) establish neuropsychological criteria for neurocognitive
SA in PLWH; (2) identify clinical predictors of SA in PLWH;
(3) assess the everyday functioning correlates of SA status.
METHODS
Participants
Participants included 734 PLWH and 123 HIV-uninfected
controls aged 50–64 years. A total of 340 PLWH were
enrolled in the NIH-funded CNSHIVAnti-Retroviral Therapy
Effects Research (CHARTER) study, consisting of six
participating university centers: Johns Hopkins University
(Baltimore, MD; n= 51); Mt. Sinai School of Medicine (New
York, NY; n= 92); University of California at San Diego
(San Diego, CA; n= 32); University of Texas Medical
Branch (Galveston, TX; n= 73); University of Washington
(Seattle, WA; n= 38); andWashington University (St. Louis,
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MO; n= 54). The remaining 394 PLWH and 123 HIV-
uninfected participants were enrolled in other NIH-funded
research studies at the University of California, San Diego’s
HIV Neurobehavioral Research Program (HNRP). All parti-
cipant visits for the present study took place between 2002
and 2017. All studies were approved by local Human Sub-
jects Protection Committees, and all participants provided
written informed consent. All PLWH were required to have
≥5 years of estimated duration of HIV disease to be con-
sidered for inclusion.
Exclusion criteria were: (1) diagnosis of psychotic or mood
disorder with psychotic features, neurological, or medical
condition that may impair neurocognitive functioning, such
as traumatic brain injury, stroke, epilepsy, or advanced liver
disease; (2) low verbal IQ of <70 as estimated by the reading
subtest of the Wide Range Achievement Test (WRAT;
Wilkinson & Robertson, 2006); or (3) evidence of intoxica-
tion by illicit drugs (except marijuana) or Breathalyzer test
for alcohol on the day of testing by positive urine toxicology.
Procedures
Neurocognitive assessment
Participants were classified as SA based on their performance
on a comprehensive and standardized battery of neuro-
cognitive tests, which has been described in detail elsewhere
(Carey et al., 2004; Heaton et al., 2010) (Table 1). Briefly, the
battery covers seven neurocognitive domains commonly
impacted in HIV-infected persons: verbal fluency, executive
functioning, processing speed, learning, delayed recall,
attention/working memory, and motor skills (Heaton et al.,
2010). Since some participants had been exposed to the test
battery at prior research visits, raw scores for each test were
converted to practice effect-adjusted scaled scores (M= 10;
SD= 3; Heaton et al., 2001). These demographically uncor-
rected scaled scores were converted to T scores (M= 50;
SD= 10) that corrected for the effects of age, education, sex,
and race/ethnicity on neurocognition (Heaton, Miller, Taylor,
& Grant, 2004; Heaton et al., 2003; Norman et al., 2011).
To generate variables that reflect maximum neurocognitive
performance at a younger age, a second set of adjusted T
scores were computed in which the age of 25, instead of
actual age, was entered into the demographic correction for-
mulas along with actual education, sex, and race/ethnicity.
These scores, referred to as “peak-age” T scores, conse-
quently compare an individual’s neurocognitive performance
to normative standards for 25-year-olds of the same educa-
tion, sex, and race/ethnicity (Heaton, Miller, et al., 2004;
Heaton et al., 2003; Norman et al., 2011). Both the actual-age
and peak-age T scores for each measure were averaged to
compute global and domain-specific T scores within each
cognitive ability area. T scores were converted to actual-age
and peak-age domain-specific deficit scores (DDS) that give
differential weight to impaired, as opposed to normal scores,
on a scale ranging from 0 (T≥ 40; normal) to 5 (T< 20;
severe impairment). DDS were then averaged to generate
an actual-age and peak-age global deficit score (GDS).
Consistent with prior studies, the presence of global impair-
ment was defined by GDS≥ 0.5 and domain-specific
impairment by DDS> 0.5 (Blackstone et al., 2012; Carey
et al., 2004).
SuperAging criteria
To estimate intact and peak neurocognitive functioning, SA
status was operationally defined as: (1) peak-age GDS< 0.5;
and (2) actual-age DDS ≤ 0.5 for all seven neurocognitive
domains. Participants that did not meet SA criteria were
Table 1. Neurocognitive tests administered by domain
Domain Test
Verbal fluency Category Fluencya
Letter Fluencya
Attention/working
memory
Paced Auditory Serial Addition Taska
WAIS–III Letter-Number Sequencingb,c
WMS-III Spatial Spanb,c
Processing speed WAIS–III Digit Symbola
WAIS–III Symbol Searcha
Trail Making Test Aa
Stroop Color & Word Test Color Scoreb,d
Executive
functioning
Wisconsin Card Sorting Test-64
Perseverative Errorsa
Trail Making Test Ba
Stroop Color & Word Test Interference
Scoreb,d
Halstead Category Testb
Learning Hopkins Verbal Learning Test–Revised
Total Learninga
Brief Visuospatial Memory Test–Revised
Total Learninga
Story Memory Test Learningb,e
Figure Memory Test Learningb,e
Delayed recall Hopkins Verbal Learning Test–Revised)
Delayed Recalla
Brief Visuospatial Memory Test–Revised
Delayed Recalla
Story Memory Test Delayed Recallb,e
Figure Memory Test Delayed Recallb,e
Motor skills Grooved Pegboard Test- Dominant Handa
Grooved Pegboard Test- Non-dominant
Handa
Note.
aCore test administered across all studies with less than 5% missing data in
the present sample.
bSupplemental test administered in select studies.
cEach study participant completed WAIS-III Letter-Number Sequencing
(n= 525) and/or WMS-III Spatial Span (n= 224).
dn= 308.
eHopkins Verbal Learning Test-Revised and Brief Visuospatial Memory
Test-Revised data were not used for learning and delayed recall domain
scores for participants who also completed Story Memory Test and Figure
Memory Test (n= 138) data.
Bolded items have the greatest influence on global neurocognitive perfor-
mance scores.
Neurocognitive SuperAging in adults with HIV 509
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1355617719000018
Downloaded from https://www.cambridge.org/core. Washington University St. Louis, on 30 May 2019 at 22:57:34, subject to the Cambridge Core terms of use, available at
classified as either cognitively normal (CN) or cognitively
impaired (CI) using the standard actual-age GDS impairment
cut-point of≥ 0.5 (Figure 1).
Neuromedical and laboratory assessment
All participants underwent a comprehensive neuromedical
assessment, including a medical history that included medi-
cations, Centers for Disease Control staging, and blood draw.
HIV infection was diagnosed by enzyme-linked immuno-
sorbent assay with Western blot confirmation. Routine clin-
ical chemistry panels, complete blood counts, rapid plasma
reagin, hepatitis C virus antibody, and CD4 + T cells (flow
cytometry) were performed at each site’s Clinical Laboratory
Improvement Amendments (CLIA)–certified, or CLIA
equivalent, medical center laboratory. Levels of HIV viral
load in plasma were measured using reverse transcriptase-
polymerase chain reaction (Amplicor, Roche Diagnostics,
Indianapolis, IN, with a lower limit of quantitation 50 copies/
mL).
Psychiatric assessment
678 PLWH had available data from the Composite Interna-
tional Diagnostic Interview (CIDI), a fully structured,
computer-based interview, to determine DSM-IV diagnoses
for current and lifetime mood and substance use disorders.
(World Health Organization, 1998). Additionally, a subset of
PLWH (n= 712) completed the Beck Depression Inventory-
II (BDI-II; Beck, Steer, & Brown, 1996) to assess current
symptoms of depressed mood.
Everyday functioning and quality of life assessment
Instrumental activities of daily living (IADL) dependence
was assessed using a revised version of the Lawton and
Brody (1969) self-report measure of everyday functioning
(Heaton, Marcotte, et al., 2004; Woods et al., 2008), in which
participants rated current abilities compared to previous
abilities across 13 everyday functioning domains. Two out-
come variables were generated: (1) A continuous variable of
the number of declines in IADL; and (2) a dichotomous
variable for IADL dependence, defined as≥2 declines at least
partially attributable to cognitive problems.
The Patient’s Assessment of Own Functioning Inventory
(PAOFI) is a 33-item self-report measure used to measure
perceived cognitive symptoms in everyday life (Chelune,
Heaton, & Lehman, 1986). Items endorsed as fairly often or
greater are considered clinically significant cognitive symp-
toms. A continuous variable for total number of clinically
significant everyday cognitive symptoms and a dichotomous
variable for employment status (i.e., employed/unemployed)
were examined as outcome variables.
A subset of PLWH (n= 490) completed the Medical
Outcome Study 36 Item Short-Form version 1.0 (MOS-
SF-36), which assesses HRQoL. The reliability and validity
of the MOS-SF-36 has been extensively documented in
PLWH (Henderson et al., 2010; Wu, Revicki, Jacobson, &
Malitz, 1997). For this study, the physical and mental health
composite scores were examined as primary outcome
variables.
Statistical Analyses
HIV group differences on neurocognitive status and demo-
graphics were examined using analyses of variance or
Kruskal-Wallis tests for continuous variables and chi-square
statistics for categorical variables. For the PLWH group only,
the same statistical tests examined neurocognitive status
group differences on demographics, HIV disease severity,
medical and psychiatric characteristics, and everyday func-
tioning outcomes. All pair-wise post hoc comparisons (SA
vs. CN, SA vs. CI, and CN vs. CI) were conducted for any
variable with at least an omnibus trend-level (i.e., p< .10)
difference across neurocognitive status groups. To control for
multiple comparisons and limit Type I error, Tukey’s honest
significant difference (HSD) tests were conducted for con-
tinuous variables and Bonferroni-corrections were applied to
chi-square tests (MacDonald & Gardner, 2000). Cohen’s d
statistics are presented for estimates of effect size for pair-
wise comparisons. All group difference analyses were per-
formed using JMP Pro version 12.0.1 (JMP®, Version
< 12.0.1> , SAS Institute Inc., Cary, NC, 1989–2007).
Next, any variable that displayed at least an omnibus trend-
level difference was entered into a multinomial regression to
determine the degree to which demographic and clinical char-
acteristics segregate according to neurocognitive status. Race/
ethnicity, sex, and education were not included in the model
because the criteria for establishing neurocognitive status
already adjusted for these factors. Actual age, however, was
included in the model since the SA criteria adjusted each parti-
cipant’s performance at peak age (i.e., 25) instead of actual age.
To determine the impact of age on global functioning
within each neurocognitive status group (PLWH only), we
conducted Pearson partial correlations between age and
demographically uncorrected global scaled scores stratified
by group, co-varying for education, sex, and race/ethnicity.
We calculated standardized Pearson partial r values that serve
as effect sizes to enhance comparability and interpretability
of the relationship between age and global neurocognitive
performance across the neurocognitive status groups. Statis-
tical differences in the magnitude of the Pearson partial cor-
relations were compared using Fisher’s r-to-z transformations
for independent correlations. Multinomial regression and
Fig. 1. Neurocognitive status criteria. SuperAging was
operationalized as a peak-age global deficit score within normal
limits (i.e., less than 0.5) and normal performance on all seven
actual-age deficit scores (i.e., less or equal than 0.5).
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Pearson’s partial correlations were performed using SPSS 24
(SPSS Inc., Chicago, IL).
RESULTS
SuperAging Prevalence
Of the 734 PLWH, 124 (17%) met criteria for SA. Of the
remaining 610 non-SA participants, 279 (38%) were CN and
331 (45%) were CI. Figure 2 displays differences in actual-
age T and peak-age T scores within and across SA and CN
PLWH with Cohen’s d effect size estimates for actual-age T
scores. The prevalence of SA and CN were significantly
higher, and prevalence of CI was significantly lower, in the
HIV-uninfected group (χ2 = 63.7; p< .0001). Of the 123
HIV-uninfected participants, 43 (35%) were SA, 67 (55%)
were CN, and 13 (11%) were CI.
Demographics
Table 2 displays PLWH neurocognitive status group differ-
ences in demographic, clinical, and neuromedical variables.
Only percent non-Hispanic white differed significantly
among demographic factors. Although the CN group exhib-
ited the lowest proportion of non-Hispanic white, no sig-
nificant pairwise differences were found. SA individuals
were on average a year younger than their CN and CI coun-
terparts and this difference approached significance, but this
did not result in significant pairwise differences. Although
groups did not differ with respect to education, SA displayed
significantly higher WRAT scores than CN (d= 0.43) and CI
(d= 0.61) participants.
Compared to PLWH, the HIV-uninfected comparison group
had significantly higher rates of non-Hispanic white partici-
pants (81% vs. 58%; p< .0001), females (38% vs. 16%;
p< .0001), mean years of education (14.4 vs. 13.6; p< .001),
and higher mean WRAT scores (106 vs. 98; p< .0001). By
design, the HIV-uninfected group did not significantly differ
from PLWH in mean age (55.5 vs. 55.1; p= .87).
HIV Disease Characteristics
A stair-step pattern of indicators of HIV disease severity was
commonly observed such that SA displayed the lowest
amount of HIV disease burden followed by CN then CI
individuals. Although this stair-step pattern occurred for
history of AIDS diagnosis, detectable plasma HIV, current
CD4 count, and nadir CD4< 200; only omnibus group dif-
ferences in current CD4< 200 were significant. Post hoc
comparisons indicated that the SA group had significantly
lower rates of participants with current CD4< 200 than the
CI group. In the full sample, participants with current
CD4< 200 were more likely to be off ART (19.6%) com-
pared to those with current CD4≥ 200 (9.8%; χ2 = 6.7;
p= .01). No noteworthy group differences were found for
estimated duration of HIV disease or receipt of ART.
Medical Comorbidities
Examination of medical comorbidities revealed significant
group differences for rates of hepatitis C virus (HCV) ser-
opositivity and diabetes. Post hoc comparisons indicated that
SA had significantly lower rates of HCV than the CN group
and lower rates of diabetes than both the CN and CI groups.
No significant group differences were found for other
Fig. 2. SuperAger (SA) versus cognitively normal (CN) differences in neurocognitive performance. Cohen’s d effect size estimates reflect
differences in actual-age T scores.
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markers of metabolic syndrome (i.e., hypertension, hyperli-
pidemia, body mass index).
Psychiatric and Substance Use Characteristics
Significant group differences were observed for rates of
lifetime cannabis use disorder and cocaine use disorder. SA
had significantly higher rates of cannabis use disorder than CI
individuals and CN individuals displayed higher rates of
cocaine use disorder than the CI group (Table 3). Although
lifetime and current diagnoses of major depressive disorder
(MDD) did not differ across groups, SA endorsed sig-
nificantly fewer depressive symptoms on the BDI-II than
both the CN (d= −0.35) and CI (d=−0.46) groups.
Multinomial Regression Predicting Neurocognitive
Status
A multinomial logistic regression was performed with the
three neurocognitive groups in PLWH as the dependent
variable. Predictors were all outcome variables from Tables 2
and 3 with a trend-level omnibus effect (excluding race/eth-
nicity, i.e., age, WRAT, current CD4< 200, HCV, diabetes,
cannabis use disorder, and BDI-II). Based on available data,
the sample size for this model included 113 SA, 259 CN, and
287 CI participants. Overall, the model was significant
(χ2(14,659)= 83.73; p< .001; Nagelkerke pseudo-R2 =
0.137). Likelihood ratio tests indicated that older age, lower
WRAT scores, diagnosis of diabetes, and higher BDI-II
scores all increased the likelihood of classification as either
CN or CI compared to SA (Table 4). Furthermore, a lifetime
diagnosis of cannabis use disorder decreased the likelihood
of classification as CI compared to SA.
To focus on a clinically relevant subgroup, we reran the
multinomial logistic regression among participants with
undetectable levels of HIV plasma RNA. Of the 535 partici-
pants with an undetectable viral load, 97 (18%) were SA, 208
(39%) were CN, and 230 (43%) were CI. Age, WRAT, BDI-
II, and diagnosis of lifetime cannabis use disorder remained
significant predictors of neurocognitive status in this virally
suppressed subgroup. Although diabetes increased likelihood
of CN (odds ratio [OR]= 1.74; p= .13) or CI (OR= 1.63;
p= .19) compared to SA, these associations were no longer
statistically significant.
Age and Global Performance Relationship by
Neurocognitive Status
To examine the relationship between age and global neuro-
cognitive performance within each neurocognitive status
Table 2. Demographic and clinical characteristics by neurocognitive status in people living with HIV
Variable
SA
(n= 124)
CN
(n= 279)
CI
(n= 331) p Pair-wise comparisonsa
Demographics
Age (years)b 54.3 (3.97) 55.2 (3.91) 55.3 (4.08) .06
Gender (male) 107 (86.3) 235 (84.2) 276 (83.4) .75
Race/ethnicity (non-Hispanic white) 79 (63.7) 142 (50.9) 203 (61.3) .01
Cognitive reserve
Education (years) 13.4 (2.58) 13.4 (2.64) 13.8 (2.69) .14
Estimated premorbid verbal IQ (WRAT) 103.5 (11.82) 98.1 (13.32) 96 (12.83) <.001 SA > CN, CI
HIV disease characteristics
History of AIDS 90 (72.6) 211 (75.6) 259 (78.3) .43
Detectable virusc 27 (21.8) 71 (25.5) 101 (30.5) .13
Current CD4 count 507 [367 – 700] 491 [333 – 691] 488 [275 – 674] .16
Current CD4< 200 9 (7.3) 31 (11.1) 52 (15.7) .03 SA<CI
Nadir CD4 count 112 [18 – 258] 96 [19 – 225] 97 [21 – 209] .72
Nadir CD4< 200 79 (63.7) 196 (70.3) 236 (71.3) .29
Years of known HIV-infection
Mean (SD) 18 (6.27) 17.9 (6.6) 17.7 (6.54) .90
Min - Max 5.6–31.1 5.4–31.0 5.2–33.7 —
On ART 107 (86.3) 249 (89.3) 297 (89.7) .59
Medical comorbidities
Hypertension 48 (38.7) 124 (44.4) 148 (44.7) .48
Hyperlipidemia 42 (33.9) 90 (32.3) 108 (32.6) .95
BMI 26.5 (5.14) 26.6 (5.03) 26 (5.08) .31
Diabetes 12 (9.7) 56 (20.1) 62 (18.7) .02 SA<CN, CI
HCV 37 (29.8) 119 (42.7) 124 (37.5) .05 SA<CN
Note. Values are presented as mean (SD), median [interquartile range], or N (%). WRAT=WRAT, reading subtest version 3 or 4. BMI= body mass index.
aPair-wise comparisons were examined using Tukey’s HSD (α= 0.05) for continuous outcomes and Bonferroni-adjustments (α= 0.05/3= 0.0167) for
dichotomous outcomes.
bRange of study sample restricted to 50–64 years for each neurocognitive status group.
cDefined as >50 copies/mL.
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group in PLWH, we performed Pearson’s partial correlations
between age and demographically-uncorrected global scaled
scores, co-varying for education, sex, and race/ethnicity. Age
negatively correlated with lower global scaled scores within
the CN (partial r= −.24; p< .001) and CI (partial r= −.15;
p< .001) groups. However, age did not significantly relate to
global scaled scores among the SA group (partial r= −.11;
p= .24). Despite this lack of significance, comparison of
Fisher’s r-to-z transformed correlations indicated that the
effect size of age on global scaled scores in SA did not sig-
nificantly differ from the effect sizes of age on global scaled
scores in CN (z= 1.23; p= .22) and CI (z= .38; p= .70).
Similarly, the magnitude of the relationship between age and
global scaled scores did not differ between CN and CI
(z= −1.15; p= .25).
Everyday Functioning and HRQoL Correlates of
Neurocognitive Status
A stair-step pattern was observed for most outcomes from the
PAOFI, IADL, and MOS-SF-36 measures, with SA indivi-
duals endorsing the most favorable everyday functioning and
HRQoL outcomes followed by CN then CI participants. SA
individuals endorsed significantly fewer cognitive symptoms
on the PAOFI than CN (d= −0.34; p< .001) and CI partici-
pants (d= −0.64; p< .0001) and fewer declines in IADLs
than either CN (d= −0.42; p< .01) or CI participants
(d= −0.70; p< .0001). The CN group also reported sig-
nificantly fewer cognitive symptoms (d= -0.30; p< .05) and
IADL declines (d= −0.33; p< .001) than the CI group. Fig-
ure 3 displays similar group differences on rates of unem-
ployment and IADL dependence as well as the MOS-SF-36
physical and mental HRQoL composite scores.
DISCUSSION
The emerging concept of neurocognitive SA has produced
invaluable insights into age-related neurocognitive pheno-
types and has undermined the widely-held assumption that
age-related neurocognitive deterioration is inevitable. How-
ever, the prospect of maintaining intact neurocognitive
capacities throughout the lifespan is highly daunting for
PLWH. In our study sample with 17% meeting criteria for
SA, we demonstrate that youthful neurocognitive perfor-
mance is possible for older PLWH. Our findings suggest that
SA status is independently related to diverse factors that
Table 3. Neuropsychiatric characteristics by neurocognitive status in people living with HIV
Variable
SA
(n= 119)
CN
(n= 264)
CI
(n= 295) p Pair-wise comparisonsa
Lifetime substance use disorders
Alcohol 72 (60.5) 145 (54.9) 164 (55.6) .57
Cannabis 48 (40.3) 91 (34.5) 76 (25.8) .01 SA > CI
Cocaine 46 (38.7) 114 (43.2) 96 (32.5) .03 CN > CI
Methamphetamine 31 (26.1) 57 (21.6) 70 (23.7) .62
Opioid 15 (12.6) 43 (16.3) 52 (17.6) .44
Depression
Lifetime MDD 66 (55.5) 160 (60.6) 182 (61.7) .50
Current MDD (n= 651) 12 (10.4) 30 (11.6) 34 (12.2) .88
BDI-II (n= 714) 8.7 (8.06) 11.9 (10.33) 13.0 (10.36) <.001 SA<CN, CI
Note. Values are presented as mean (SD) or N (%). BDI-II=BDI-II total score.
aPair-wise comparisons were examined using Tukey’s HSD. (α= 0.05) for BDI-II and Bonferroni-adjustment (α= 0.05/3= 0.0167) for diagnosis variables.
Table 4. Multinomial logistic regression predicting neurocognitive status in people living with HIV
Outcome: Classification as CN (reference: SA) Outcome: Classification as CI (reference: SA)
Predictor OR 95% CI p Predictor OR 95% CI p
Age 1.10 [1.03, 1.17] <.001 Age 1.11 [1.05, 1.19] .001
WRAT 0.96 [0.94, 0.98] <.001 WRAT 0.95 [0.93, 0.97] <.001
CD4< 200 1.40 [0.60, 3.26] .63 CD4<200 1.98 [0.86, 4.51] .11
HCV 1.32 [0.80, 2.18] .28 HCV 0.97 [0.59, 1.62] .92
Diabetes 2.23 [1.11, 4.47] .02 Diabetes 2.14 [1.06, 4.33] .03
Cannabis 0.74 [0.46, 1.20] .22 Cannabis 0.46 [0.28, 0.75] .002
BDI-II 1.04 [1.02, 1.07] <.001 BDI-II 1.06 [1.03, 1.09] <.001
95% CI= 95% confidence interval; WRAT=WRAT, reading subtest version 3 or 4; Cannabis= lifetime cannabis use disorder; BDI-II=BDI-II total score.
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reflect current physical and mental health as well as pre-
morbid neurocognitive functioning. Furthermore, SA status
is associated with better every day functioning, supporting
the ecological validity of distinguishing SA from CN and CI
individuals.
Given the marked difference in average age between our
cohort of older PLWH and previous SA cohorts of healthy
elders, our SA criteria and study results cannot be directly
linked to the extant SA literature. However, there are several
strengths of our peak-age approach to defining neurocogni-
tive SA in the context of HIV infection. First, we do not focus
on one specific domain of neurocognitive functioning.
Instead, our SA criteria are defined by absence of peak-age
impairment in global neurocognitive functioning and absence
of actual-age impairment in all domains assessed. PLWH are
a heterogeneous group whose neurocognition may be
impacted by HIV and demographic and clinical confounds,
contributing to a neurocognitive profile that is not defined by
deficits in any one neurocognitive domain. Thus, we
demonstrate merit in defining SA by global performance to
match what is known about neurocognitive functioning
among PLWH.
An important feature of our global estimates of neuro-
cognitive functioning is that they are adjusted for practice
effects, as some study participants had prior exposure to the
neurocognitive testing battery. Practice, or learning, effects
complicate assessment of SA because seemingly elite neu-
rocognition can be an artifact of prior testing experience. By
correcting for normal test–retest fluctuations, we reduce the
likelihood of overestimating neurocognitive ability and
enhance the stringency of our SA criteria.
We compared neurocognitive functioning of our sample to
normative standards for age 25 when neurocognitive func-
tioning is maximal (Salthouse, 2009). The concept of SA
(Rogalski et al., 2013) posits that, within an individual’s adult
life, aging does not necessitate neurocognitive decline.
Rather, aging increases the likelihood of encountering
adverse events that contribute to neuronal damage and
decline in neurocognition. Defining SA in this way may
facilitate understanding of the kinds of events or experiences
that either support, or damage, neurocognitive functioning.
SA had lower rates of unemployment and IADL depen-
dence than the other neurocognitive status groups and
higher self-reported physical and mental HRQoL. Thus, our
method for defining SA appears to be concurrently valid
with measures of everyday functioning and HRQoL.
Importantly, CN and SA groups differ in real-world out-
comes, indicating heterogeneity among neurocognitively
unimpaired individuals. Unlike prior investigations of SA,
our definition of SA did not require self-reported IADL
independence as a criterion. Despite performance-based
data indicating SA, a small proportion of the SA group
endorsed IADL dependence. Among our SA group, self-
reported declines in IADL may represent actual decline,
such that SA individuals may have started at higher levels of
functioning and experienced a decline that is not necessarily
at an impaired level.
To this point, our measure of IADL dependence may be
overly sensitive in detecting decline and not specific in
detecting whether this decline represents a shift from within
normal functioning to impairment status. Given that most
other studies rely on absence of IADL dependence or decline
when defining SA, these studies may be potentially mis-
identifying SA individuals who perform at peak-age levels on
neurocognitive tests. Thus, future investigations need to
consider the appropriate use of performance-based versus
self-reported deficits when classifying individuals as SA
versus CN.
Fig. 3. Everyday functioning and HRQoL by neurocognitive status. Risk ratio (RR) estimates represent the reduction in risk of IADL
dependence or unemployment for each pair-wise comparison. Cohen’s d effect size estimates reflect differences in HRQoL for each pair-
wise comparison. All p-values are significant after Bonferroni-adjustment or Tukey’s HSD. ***p< .001; **p< .01; *p< .05.
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Consistent with prior research, the WRAT reading subtest,
an estimate of premorbid verbal IQ that is relatively resistant
to HIV-associated neurocognitive decline (Casaletto et al.,
2014), was higher in SA and predicted SA status. Moore et al.
(2014) demonstrated a positive correlation between a com-
posite measure of cognitive reserve, including verbal IQ, and
successful cognitive aging in older PLWH. The theory of
cognitive reserve postulates that effects of neural insults, such
as age and comorbidities, are buffered by robust brain net-
works (Stern, 2002). Although operational definitions and
methods of quantifying cognitive reserve may vary across
studies (Moore et al., 2014; Nucci, Mapelli, & Mondini,
2012; Reed et al., 2010; Selzam et al., 2017), cognitive
reserve is considered to reflect a combination of genetically-
driven intellectual capacity and cognitively stimulating life
experiences that promote resilience against age-related neu-
rocognitive decline (Daffner, 2010; Stern, 2012).
Although SA displayed higher premorbid functioning on
the WRAT, neurocognitive status groups did not differ on
years of education. Thus, neuroprotective benefits measured
by higher WRAT performance may be better explained by
factors other than education, such as genetically driven neu-
rocognitive resilience. More granular methods of quantifying
both the genetic (e.g., polygenic risk scores) and environ-
mental (e.g., educational quality, socioeconomic factors)
loadings of cognitive reserve are needed to thoroughly
address questions regarding premorbid functioning and age-
related neuroprotection.
Among HIV-uninfected individuals, diabetes is also
strongly associated with neurocognitive impairment and is
considered to be a predisposing factor for later development
of vascular dementia and Alzheimer’s disease (Cheng,
Huang, Deng, & Wang, 2012; Taguchi, 2009). Insulin
resistance and diabetes are associated with MRI structural
abnormalities and functional alterations of the blood brain
barrier, resulting in processes that facilitate the pathogenesis
and progression of neurocognitive impairment (Archibald
et al., 2014; Mogi & Horiuchi, 2011; Prasad, Sajja, Naik, &
Cucullo, 2014). We found a stair-step effect for the influence
of diabetes on neurocognitive status such that CI individuals
were characterized by the highest rates of diabetes, followed
by CN, and then SA participants; associations between dia-
betes and neurocognitive status remained in multivariable
analyses.
Other studies have found similar increases in risk for
HAND among HIV-infected persons with self-reported dia-
betes or elevated fasting insulin levels (McCutchan et al.,
2012; Valcour et al., 2006, 2005; Vance et al., 2014). Thus,
for SA participants, their relatively low incidence of diabetes
likely contributed to better neurocognitive functioning.
However, the effect of diabetes was not significant when
restricting our multinomial regression analysis to virally
suppressed participants, underscoring the importance of other
contributing factors to SA status.
SA had lower BDI-II scores than both CN and CI uni-
variately and in the multinomial logistic regression. In con-
trast, rates of current and lifetime MDD diagnoses did not
significantly differ by neurocognitive status group, indicating
that among older PLWH, current subclinical depressive
symptoms are associated with neurocognitive functioning
more closely than active or remote clinical depression. This
relationship may reflect known neurological consequences of
depression, including neuroinflammation and associated
neuronal damage, apoptosis, and reduced neurogenesis
(Kubera, Obuchowicz, Goehler, Brzeszcz, & Maes, 2011;
Maes et al., 2009). Behavioral mechanisms may also underlie
the relationship between depression and neurocognition, as
depressive symptoms (even those that are subclinical) nega-
tively impact engagement in activities known to promote
neurocognitive health, including exercise, healthy nutrition,
and social activity (Jeste, Depp, & Vahia, 2010; Moore et al.,
2018; Vahia et al., 2010).
SA displayed greater rates of lifetime cannabis use dis-
order in comparison to CI, and this pattern also remained
significant in the multinomial logistic regression. This result
is supported by evidence suggesting neuroprotective effects
of cannabis use through activation of cannabinoid receptors
(i.e., CB1 and CB2) in the central nervous system (Sanchez &
Garcia-Merino, 2012). Specifically, CB1 agonists reduce
excitotoxity in post-synaptic neurons (Marsicano et al., 2003)
while CB2 agonists promote anti-inflammatory and immu-
nomodulatory actions (Rom & Persidsky, 2013).
Nevertheless, the relationship between cannabis use and
brain integrity among PLWH and HIV-uninfected adults
remains a controversial matter. While chronic cannabis use
has been associated with neurometabolic abnormalities,
reduced gray matter volumes, and memory deficits in cohorts
comprised of PLWH and seronegative controls (Battistella
et al., 2014; Chang, Cloak, Yakupov, & Ernst, 2006;
Cristiani, Pukay-Martin, & Bornstein, 2004; Thames et al.,
2017), emerging evidence suggests that active cannabis use
may limit HIV viral replication and attenuate HIV-related
immunosuppression, inflammation, and cerebral glutamate
depletion (Chang et al., 2006; Rizzo et al., 2018; Thames,
Mahmood, Burggren, Karimian, & Kuhn, 2016). These
neuroprotective properties of the cannabinoid system are not
referenced in the context of a cannabis use disorder, which
may reflect problematic use or heavy exposure that could
exceed therapeutic levels.
Moreover, prior studies examining elite neurocognition in
healthy elders have excluded participants with substance use
histories that could influence neurocognition. Thus, our
cannabis-related findings cannot be compared to prior SA
studies and the relationship between cannabis use disorder
and neuroprotection in HIV remains poorly characterized.
Future research is needed to explore therapeutic levels of
cannabis use and identify potential benefits of cannabinoid
receptor activation on neurocognition among PLWH.
Despite stair-step patterns for HIV disease characteristics
in SA individuals compared to CN and CI participants, only
the proportion of participants with current CD4 counts below
200 was statistically significantly different among the neu-
rocognitive status groups. Specifically, the SA group had a
lower proportion with current CD4 counts below 200 than the
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CI group. However, this difference was not statistically sig-
nificant when controlling for other clinical and demographic
variables (e.g., age, WRAT, and depressive symptoms).
Unexpectedly, the SA and CN groups had low nadir CD4
counts comparable to the CI group, possibly reflecting
underlying resilience to the “legacy” effects of advanced
immunosuppression.
In a comparison of predictors of HAND before and during
the era of ART, only low nadir CD4 was found to increase
risk of neurocognitive impairment in both treatment eras
(Heaton et al., 2011). However, when examining factors
associated with decline to symptomatic HAND, current CD4
also predicted decline to symptomatic status (Grant et al.,
2014). SA with current CD4 counts below 200 were more
likely to be off ART. Furthermore, the higher proportion of
participants with CD4 counts below 200 in the CI group may
result from poorer ART adherence that is a consequence of
their cognitive impairment. Given that the majority of parti-
cipants were likely to begin ART after having advanced HIV,
it is unclear whether similar relationships between HIV dis-
ease severity and neurocognitive status exist for modern era
patients who typically start treatment at earlier stages.
The observation that SA prevalence was twice as high in
HIV-uninfected comparison participants as compared to
PLWH provides important context to our findings. This dif-
ference, in addition to the higher prevalence of CN and lower
prevalence of CI in HIV-uninfected controls, aligns with the
known independent neurotoxic effects of HIV and potential
synergistic effects of aging with HIV. Compared to their
seronegative counterparts, older PLWH must withstand a
greater amount of exposure to neural insults to sustain an elite
level of neurocognitive performance. It is important to note
that the HIV-uninfected group was demographically distinct
from the PLWH group, as indicated by a higher prevalence of
non-Hispanic whites, more years of education, and better
WRAT Reading scores. Thus, the estimated two-fold differ-
ence in SA prevalence may be partially confounded by
potential socio-demographic advantages of the HIV-
uninfected group.
Several limitations to the present study warrant discussion.
Our peak-age corrected neurocognitive scores, based on a
normative sample of 25-year-olds, serve as proxy measures
for neurocognitive resilience and do not directly capture the
true within-subject change in neurocognitive performance
since age 25. Because our data are cross-sectional, we cannot
rule out the possibility that members of the SA group have
experienced considerable lifetime neurocognitive decline and
that their SA status is an artifact of superior baseline neuro-
cognitive capacity. Although our analysis demonstrating that
older age was associated with lower global scaled scores in
CN and CI groups, but not the SA group, preliminarily sup-
ports the validity of our SA criteria, the magnitude of these
age effects were small and did not significantly differ across
groups. In addition to other factors importantly contributing
to variance in global neurocognitive performance, these small
effect sizes are likely influenced by the narrow age range of
our sample.
Our results highlight clinically informative predictors and
benefits of neurocognitive resilience; yet, the racial/ethnic
composition of our sample was predominantly non-Hispanic
white men and may limit the generalizability of our findings
to more socio-demographically diverse populations. Fur-
thermore, our cohort of older PLWH is relatively young
compared to the healthy adult cohorts studied in the extant
SA literature of persons not living with HIV, but the age
range is indicative of some of the oldest PLWH with a suf-
ficient sample size to be studied. Although the inclusion of an
age-matched HIV-uninfected comparison group provided an
informative anchor point for SA prevalence in healthy adults,
this comparison group was not comparable to the PLWH
group on other important demographic factors. Conse-
quently, important questions remain regarding the extent to
which our definition of SA in PLWH reflects resilience to the
effects of HIV and aging into late adulthood, which may only
be adequately addressed with data from ideal comparison
groups. As the proportion of PLWH older than 65 years of
age increases, longitudinal cohort studies of PLWH will be
better equipped to address critical questions related to the
prevalence, stability, and impact of SA in PLWH compared
to healthy seniors.
Although we focused on evaluating the relationships
between SA status and clinical correlates commonly assessed
in PLWH, the absence of biomarker data indicative of central
nervous system integrity (e.g., neuroimaging, cerebrospinal
fluid assays) prevents us from determining the neurobiolo-
gical correlates of SA status. Additionally, an assessment of
modifiable behaviors (e.g., physical activity, neurocognitive
activity, positive psychological outlook) that may mediate
the relationships between SA status and psychosocial, med-
ical, and everyday functioning correlates could help to
prioritize research in clinical interventions to increase the
fraction of SA in PLWH (Vance & Burrage, 2006).
Taken together, our results demonstrate that a substantial
fraction of older, HIV-infected patients maintain their max-
imal neurocognitive abilities that confer real-world benefits
even compared to patients with normal age-related cognitive
decline. Although HIV disease negatively impacts the pre-
valence of SA, our findings highlight the clinical value in
identifying neurocognitive resilience within PLWH and
focus on the potential for positive outcomes despite aging
with HIV. Examination of the stability of SA status through
longitudinal analysis, exploration of biological and genetic
markers of neuronal integrity, and assessment of modifiable
lifestyle factors should enhance studies of future interven-
tions to improve neurocognitive aging in older PLWH.
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